The Australian Advantage: Why U.S. Sponsors Should Conduct Clinical Trials Down Under

Trial sponsors weighing where to site oncology, immunology, and rare disease studies increasingly find Australia climbing the shortlist alongside traditional U.S. and European locations. With no IND requirement, ethics and regulatory approvals typically completed in four to six weeks, and R&D tax offsets reaching 43.5% for eligible smaller companies, the country compresses start-up timelines well below U.S. benchmarks. A diverse, English-speaking patient population and ISO-certified trial infrastructure add further appeal for sponsors managing cost and speed pressures.

This paper compares Australia's regulatory pathway, financial incentives, and trial volumes against U.S. norms, outlining where the advantage is strongest and where trade-offs remain. Download the paper below to learn more about Australia's growing role in global trial strategy.